Compare · GILD vs INAB
GILD vs INAB
Side-by-side comparison of Gilead Sciences Inc. (GILD) and IN8bio Inc. (INAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and INAB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.03B, about 10783.7x INAB ($14.4M).
- Over the past year, GILD is up 18.1% and INAB is down 34.9% - GILD leads by 53.0 points.
- GILD has been more active in the news (17 items in the past 4 weeks vs 4 for INAB).
- GILD has more recent analyst coverage (25 ratings vs 5 for INAB).
- Company
- Gilead Sciences Inc.
- IN8bio Inc.
- Price
- $125.43+0.48%
- $1.46-1.02%
- Market cap
- $155.03B
- $14.4M
- 1M return
- -3.85%
- -3.64%
- 1Y return
- +18.14%
- -34.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 17
- 4
- Recent ratings
- 25
- 5
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
IN8bio Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest GILD
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
Latest INAB
- IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
- IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
- SEC Form 8-K filed by IN8bio Inc.
- SEC Form 424B5 filed by IN8bio Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by IN8bio Inc.
- Director Fairbairn Emily gifted 724,637 shares (SEC Form 4)
- SEC Form EFFECT filed by IN8bio Inc.
- Amendment: SEC Form S-3/A filed by IN8bio Inc.
- IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
- SEC Form 4 filed by Director Epperly Corinne